Organization
Lung Cancer Group Cologne
2 clinical trials
2 abstracts
Clinical trial
A Phase II Trial of Nivolumab in Combination With Ipilimumab to Evaluate Efficacy and Safety Relapsed in Lung Cancer and to Evaluate Biomarkers Predictive for Response to Immune Checkpoint InhibitionStatus: Completed, Estimated PCD: 2022-08-31
Abstract
Response to targeted and immune therapy in patients with NSCLC and BRAF non-V600E mutations: A retrospective, multicenter analysis within the national Network Genomic Medicine Lung Cancer (nNGM) in Germany.Org: DKFZ-Hector Cancer Institute, Network Genomic Medicine, TU Dresden, Justus-Liebig-University, University Hospital Frankfurt,
Clinical trial
A Phase II Trial to Evaluate Efficacy and Safety of Erdafitinib in Patients With Advanced Non Small Cell Lung Carcinoma (NSCLC) Harboring Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations After Relapse of Standard Therapy.Status: Terminated, Estimated PCD: 2022-09-30
Abstract
Class II and class III BRAF mutations in patients with advanced non-small cell lung cancer (NSCLC): Clinical characteristics, mutation patterns, and survival outcomes.Org: Network Genomic Medicine, University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne,